162 related articles for article (PubMed ID: 27491708)
41. AMG 580: a novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer.
Chen H; Lester-Zeiner D; Shi J; Miller S; Glaus C; Hu E; Chen N; Able J; Biorn C; Wong J; Ma J; Michelsen K; Hill Della Puppa G; Kazules T; Dou HH; Talreja S; Zhao X; Chen A; Rumfelt S; Kunz RK; Ye H; Thiel OR; Williamson T; Davis C; Porter A; Immke D; Allen JR; Treanor J
J Pharmacol Exp Ther; 2015 Feb; 352(2):327-37. PubMed ID: 25502803
[TBL] [Abstract][Full Text] [Related]
42. Addressing phototoxicity observed in a novel series of biaryl derivatives: discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436.
Hamaguchi W; Masuda N; Miyamoto S; Kikuchi S; Narazaki F; Shiina Y; Seo R; Amano Y; Mihara T; Moriguchi H; Hattori K
Bioorg Med Chem; 2015 Jul; 23(13):3351-67. PubMed ID: 25960322
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part I.
Das S; Harde RL; Shelke DE; Khairatkar-Joshi N; Bajpai M; Sapalya RS; Surve HV; Gudi GS; Pattem R; Behera DB; Jadhav SB; Thomas A
Bioorg Med Chem Lett; 2014 May; 24(9):2073-8. PubMed ID: 24725435
[TBL] [Abstract][Full Text] [Related]
44. Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.
Kawamoto Y; Tomino M; Hiramatsu K; Oyama Y; Hayashi Y
Bioorg Med Chem Lett; 2019 Jun; 29(11):1419-1422. PubMed ID: 30952590
[TBL] [Abstract][Full Text] [Related]
45. N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.
Kilburn JP; Kehler J; Langgård M; Erichsen MN; Leth-Petersen S; Larsen M; Christoffersen CT; Nielsen J
Bioorg Med Chem; 2013 Oct; 21(19):6053-62. PubMed ID: 23978358
[TBL] [Abstract][Full Text] [Related]
46. Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.
Megens AA; Hendrickx HM; Hens KA; Fonteyn I; Langlois X; Lenaerts I; Somers MV; de Boer P; Vanhoof G
J Pharmacol Exp Ther; 2014 Apr; 349(1):138-54. PubMed ID: 24421319
[TBL] [Abstract][Full Text] [Related]
47. Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.
Koizumi Y; Tanaka Y; Matsumura T; Kadoh Y; Miyoshi H; Hongu M; Takedomi K; Kotera J; Sasaki T; Taniguchi H; Watanabe Y; Takakuwa M; Kojima K; Baba N; Nakamura I; Kawanishi E
Bioorg Med Chem; 2019 Aug; 27(15):3440-3450. PubMed ID: 31235264
[TBL] [Abstract][Full Text] [Related]
48. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Raheem IT; Breslin MJ; Fandozzi C; Fuerst J; Hill N; Huszar S; Kandebo M; Kim SH; Ma B; McGaughey G; Renger JJ; Schreier JD; Sharma S; Smith S; Uslaner J; Yan Y; Coleman PJ; Cox CD
Bioorg Med Chem Lett; 2012 Sep; 22(18):5903-8. PubMed ID: 22892116
[TBL] [Abstract][Full Text] [Related]
49. Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines.
Wagner S; Scheunemann M; Dipper K; Egerland U; Hoefgen N; Steinbach J; Brust P
Eur J Med Chem; 2016 Jan; 107():97-108. PubMed ID: 26562545
[TBL] [Abstract][Full Text] [Related]
50. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.
Wu Y; Zhou Q; Zhang T; Li Z; Chen YP; Zhang P; Yu YF; Geng H; Tian YJ; Zhang C; Wang Y; Chen JW; Chen Y; Luo HB
J Med Chem; 2019 Apr; 62(8):4218-4224. PubMed ID: 30916555
[TBL] [Abstract][Full Text] [Related]
51. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia.
Cutshall NS; Onrust R; Rohde A; Gragerov S; Hamilton L; Harbol K; Shen HR; McKee S; Zuta C; Gragerova G; Florio V; Wheeler TN; Gage JL
Bioorg Med Chem Lett; 2012 Sep; 22(17):5595-9. PubMed ID: 22841436
[TBL] [Abstract][Full Text] [Related]
52. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
[TBL] [Abstract][Full Text] [Related]
53. Particle swarm optimization and genetic algorithm as feature selection techniques for the QSAR modeling of imidazo[1,5-a]pyrido[3,2-e]pyrazines, inhibitors of phosphodiesterase 10A.
Goodarzi M; Saeys W; Deeb O; Pieters S; Vander Heyden Y
Chem Biol Drug Des; 2013 Dec; 82(6):685-96. PubMed ID: 23906083
[TBL] [Abstract][Full Text] [Related]
54. Novel nanomolar imidazo[4,5-b]pyridines as selective nitric oxide synthase (iNOS) inhibitors: SAR and structural insights.
Grädler U; Fuchss T; Ulrich WR; Boer R; Strub A; Hesslinger C; Anézo C; Diederichs K; Zaliani A
Bioorg Med Chem Lett; 2011 Jul; 21(14):4228-32. PubMed ID: 21684157
[TBL] [Abstract][Full Text] [Related]
55. Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.
Helal CJ; Kang Z; Hou X; Pandit J; Chappie TA; Humphrey JM; Marr ES; Fennell KF; Chenard LK; Fox C; Schmidt CJ; Williams RD; Chapin DS; Siuciak J; Lebel L; Menniti F; Cianfrogna J; Fonseca KR; Nelson FR; O'Connor R; MacDougall M; McDowell L; Liras S
J Med Chem; 2011 Jul; 54(13):4536-47. PubMed ID: 21650160
[TBL] [Abstract][Full Text] [Related]
56. New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
Ručilová V; Świerczek A; Vanda D; Funk P; Lemrová B; Gawalska A; Bucki A; Nowak B; Zadrożna M; Pociecha K; Soural M; Wyska E; Pawłowski M; Chłoń-Rzepa G; Zajdel P
Eur J Med Chem; 2021 Jan; 209():112854. PubMed ID: 33022582
[TBL] [Abstract][Full Text] [Related]
57. PDE-10A inhibitors as insulin secretagogues.
Cantin LD; Magnuson S; Gunn D; Barucci N; Breuhaus M; Bullock WH; Burke J; Claus TH; Daly M; Decarr L; Gore-Willse A; Hoover-Litty H; Kumarasinghe ES; Li Y; Liang SX; Livingston JN; Lowinger T; Macdougall M; Ogutu HO; Olague A; Ott-Morgan R; Schoenleber RW; Tersteegen A; Wickens P; Zhang Z; Zhu J; Zhu L; Sweet LJ
Bioorg Med Chem Lett; 2007 May; 17(10):2869-73. PubMed ID: 17400452
[TBL] [Abstract][Full Text] [Related]
58. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T
J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and SAR study of novel tricyclic pyrazoles as potent phosphodiesterase 10A inhibitors.
Dore A; Asproni B; Scampuddu A; Pinna GA; Christoffersen CT; Langgård M; Kehler J
Eur J Med Chem; 2014 Sep; 84():181-93. PubMed ID: 25016376
[TBL] [Abstract][Full Text] [Related]
60. Characterization of binding and inhibitory properties of TAK-063, a novel phosphodiesterase 10A inhibitor.
Harada A; Suzuki K; Kamiguchi N; Miyamoto M; Tohyama K; Nakashima K; Taniguchi T; Kimura H
PLoS One; 2015; 10(3):e0122197. PubMed ID: 25815469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
